The Course of COVID-19 in Inflammatory Bowel Disease: Protective Role of TNF Antagonists

被引：5

作者：

Cappello, Maria ^{[1
]}

Busacca, Anita ^{[1
]}

Guida, Laura ^{[1
]}

机构：

[1] Univ Palermo, Gastroenterol & Hepatol Sect, Promise, Palermo, Italy

来源：

GASTROENTEROLOGY | 2021年 / 160卷 / 05期

关键词：

D O I：

10.1053/j.gastro.2020.06.087

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1885 / 1886

页数：3

共 3 条

[1]

Bezzio C, 2020, GUT, P1

[2] Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry [J].

Brenner, Erica J. ;

Ungaro, Ryan C. ;

Gearry, Richard B. ;

Kaplan, Gilaad G. ;

Kissous-Hunt, Michele ;

Lewis, James D. ;

Ng, Siew C. ;

Rahier, Jean-Francois ;

Reinisch, Walter ;

Ruemmele, Frank M. ;

Steinwurz, Flavio ;

Underwood, Fox E. ;

Zhang, Xian ;

Colombel, Jean-Frederic ;

Kappelman, Michael D. .

GASTROENTEROLOGY, 2020, 159 (02) :481-+

[3] Market share and costs of biologic therapies for inflammatory bowel disease in the USA [J].

Yu, H. ;

MacIsaac, D. ;

Wong, J. J. ;

Sellers, Z. M. ;

Wren, A. A. ;

Bensen, R. ;

Kin, C. ;

Park, K. T. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (03) :364-370

← 1 →